Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

Benzinga · 2d ago
Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.